License agreement with NIAID for VRC07-523LS broadly neutralizing antibody


National Institute of Allergy and Infectious Diseases (NIAID) of US NIH and TaiMed Biologics USA (100% subsidiary of TaiMed Inc.) finally agreed on October 2, 2019 to sign a world-wide, non-exclusive license under the NIAID Patent Rights to develop and commercialize the VRC07-523LS broadly neutralizing antibody for providing an effective treatment against HIV. TaiMed will combine with VRC07-523LS and TMB-Bispecific Antibodies for drug development targeting as the HIV second-line treatment therapy in the future. The license terms cannot be disclosure based on the mutual confidential agreement in the contract.